Merck Raises Long-Term Revenue Outlook to $70 Billion by Mid-2030s
Merck has raised its long-term revenue outlook, projecting $70 billion from new growth drivers by the mid-2030s.12
Cardiometabolic and respiratory treatments expected to generate $20 billion, up from $15 billion previously.1
Infectious disease drugs projected to contribute $15 billion, increased from $5 billion.1
Announcement reported on January 13, 2026, amid acceleration of new drug launches ahead of Keytruda competition.12
Sources:
1. https://www.indexbox.io/blog/merck-raises-long-term-outlook-for-new-growth-drivers/
2. https://swingtradebot.com/news-articles/22389925-merck-lifts-longterm-revenue-target